In:
Acta Haematologica, S. Karger AG, Vol. 145, No. 2 ( 2022), p. 132-143
Kurzfassung:
〈 b 〉 〈 i 〉 Introduction: 〈 /i 〉 〈 /b 〉 The clinical implications of plasma Epstein-Barr virus (EBV) DNA in patients with peripheral T-cell lymphoma (PTCL) remain unclear. 〈 b 〉 〈 i 〉 Objective: 〈 /i 〉 〈 /b 〉 This study aimed to explore the clinical correlations of pre- and post-treatment plasma EBV-DNA concentrations with treatment outcomes and prognosis in patients with PTCL. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 We retrospectively reviewed 128 patients diagnosed with PTCL with available data on pre-treatment plasma EBV-DNA, including 63 patients for whom post-treatment plasma EBV-DNA data were also available. Patients with extra-nodal NK/T- 〈 X00_Del_TrennDivis 〉 〈 /X00_Del_TrennDivis 〉 cell lymphoma were excluded from this study. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 Pre-treatment plasma EBV-DNA was elevated (e.g., ≥500 copies/mL) in 35.2% of PTCL patients, with significant differences in positive rates between different subtypes of PTCL ( 〈 i 〉 p 〈 /i 〉 & #x3c; 0.001). High pre-treatment EBV-DNA concentrations were associated with advanced age ( & #x3e;60 years), elevated lactate dehydrogenase levels, high International Prognostic Index (IPI), and positive EBV-encoded RNAs-ISH in tumor specimens. In multivariate analyses, pre-treatment EBV-DNA ≥500 copies/mL was an independent prognostic factor after adjusting for IPI and pathological subtypes (hazard ratio = 2.14, 〈 i 〉 p 〈 /i 〉 = 0.032). For patients with elevated pre-treatment EBV-DNA, normalization of EBV-DNA concentrations after first-line chemotherapy was significantly associated with better overall response rate (81.3% vs. 22.2%, 〈 i 〉 p 〈 /i 〉 = 0.014), progression-free survival (12.0 months vs. 3.7 months, 〈 i 〉 p 〈 /i 〉 = 0.011), and overall survival (37.9 months vs. 7.8 months, 〈 i 〉 p 〈 /i 〉 = 0.012). For patients achieving remission to first-line therapy, rebound of EBV-DNA levels during follow-up was associated with disease relapse or progression. 〈 b 〉 〈 i 〉 Conclusions: 〈 /i 〉 〈 /b 〉 These results suggest that pre-treatment plasma EBV-DNA concentration is a strong prognostic factor for PTCL. For patients with elevated pre-treatment EBV-DNA, dynamic monitoring of EBV-DNA changes after initiation of therapy is useful for predicting treatment outcome and disease relapse.
Materialart:
Online-Ressource
ISSN:
0001-5792
,
1421-9662
Sprache:
Englisch
Verlag:
S. Karger AG
Publikationsdatum:
2022
ZDB Id:
1481888-7
ZDB Id:
80008-9
Permalink
